# Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

> **NCT02229396** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 695 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Exantide with Dapagliflozin
- **DRUG:** Exentide
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT02229396
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-04
- **Primary completion:** 2016-04-26
- **Final completion:** 2017-12-28
- **Target enrollment:** 695 (ACTUAL)
- **Last updated:** 2018-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229396, "Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02229396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*